我国上市中药企业专利质量研究——基于研发投入视角
|
摘要
近年来,我国中药发明专利申请量迅速攀升,但授权率却呈下降趋势。上市中药企业是该领域创新较为活跃的群体,因此该文通过将专利申请及授权情况与企业R&D投入情况相结合,分析了它们的专利质量,以期探索提高中药专利质量切实可行的方法。研究得出以下结论:我国上市中药企业整体R&D投入不足,各企业间差距较大;上市中药企业专利申请意识较好,专利申请数量基本处于合理范围,但部分企业仍存在非正常专利申请现象,专利质量有待提升;此外企业的专利运营能力仍有待提升。针对这种现象,企业应切实提高科学研究与试验发展(R&D)投入,加强技术创新水平,提高专利运营能力,自觉杜绝"非正常专利"的产出;专利行政部门则应优化有利于专利质量提升的政策导向,把握正常合理的审查尺度,共同逐步提升中药专利的质量。
In recent years,the number of patent applications for traditional Chinese medicine( TCM) inventions has increased rapidly,but the authorization rate has declined. Listed TCM enterprises are a group of active innovators in this field,so this paper analyzes their patent quality by combining patent application and authorization with R&D investment of enterprises in order to explore a practical way to improve the quality of TCM patents. The conclusions are as follows: the R&D investment of listed TCM enterprises is insufficient and the gap between enterprises is large; the number of patent applications is within a reasonable range,but some enterprises still have abnormal patent applications,and patent quality needs to be improved; in addition,the patent operation capacity of enterprises still needs to be improved. In this phenomenon,enterprises should improve R&D investment,strengthen the level of technological innovation,improve the ability of patent operation,and consciously eliminate the output of " abnormal patents"; the patent administrative department should optimize policy direction which is beneficial to the improvement of patent quality,grasp the normal and reasonable examination scale,and jointly improve the quality of TCM patents.
In recent years,the number of patent applications for traditional Chinese medicine( TCM) inventions has increased rapidly,but the authorization rate has declined. Listed TCM enterprises are a group of active innovators in this field,so this paper analyzes their patent quality by combining patent application and authorization with R&D investment of enterprises in order to explore a practical way to improve the quality of TCM patents. The conclusions are as follows: the R&D investment of listed TCM enterprises is insufficient and the gap between enterprises is large; the number of patent applications is within a reasonable range,but some enterprises still have abnormal patent applications,and patent quality needs to be improved; in addition,the patent operation capacity of enterprises still needs to be improved. In this phenomenon,enterprises should improve R&D investment,strengthen the level of technological innovation,improve the ability of patent operation,and consciously eliminate the output of " abnormal patents"; the patent administrative department should optimize policy direction which is beneficial to the improvement of patent quality,grasp the normal and reasonable examination scale,and jointly improve the quality of TCM patents.
引文
[1]曹洪欣.中医药是我国具有原创优势的科技资源[N].光明日报,2015-10-17(010).
[2]郭良玉,杨婧,杨旭杰.专利运营驱动中药企业竞争优势形成价值分析[J].中国中医药信息杂志,2016,23(8):7.
[3]寇学芳,徐文.浅析我国中药专利保护的现状与对策[J].中国药物警戒,2016,13(9):533.
[4]冯雪飞,袁红梅.中国中药领域专利情报分析[J].中国新药杂志,2018,27(4):379.
[5]吕申,李巍巍.高新技术企业专利申请质量提升的方法---以专利技术交底书的撰写为例[J].江苏科技信息,2018(35):14.
[6]耿胜燕,耿立东,欧阳雪宇.我国中药专利申请质量的现状分析与对策研究[J].中国中医信息杂志,2016,23(1):18.
[7]程江雪.中药提取物组合物的专利信息分析及专利保护研究[D].北京:北京中医药大学,2016.
[8]王楠,郭凯,程心旻,等.INDENASPA公司的银杏叶制剂专利网[J].中国中药杂志,2015,40(19):3889.
[2]郭良玉,杨婧,杨旭杰.专利运营驱动中药企业竞争优势形成价值分析[J].中国中医药信息杂志,2016,23(8):7.
[3]寇学芳,徐文.浅析我国中药专利保护的现状与对策[J].中国药物警戒,2016,13(9):533.
[4]冯雪飞,袁红梅.中国中药领域专利情报分析[J].中国新药杂志,2018,27(4):379.
[5]吕申,李巍巍.高新技术企业专利申请质量提升的方法---以专利技术交底书的撰写为例[J].江苏科技信息,2018(35):14.
[6]耿胜燕,耿立东,欧阳雪宇.我国中药专利申请质量的现状分析与对策研究[J].中国中医信息杂志,2016,23(1):18.
[7]程江雪.中药提取物组合物的专利信息分析及专利保护研究[D].北京:北京中医药大学,2016.
[8]王楠,郭凯,程心旻,等.INDENASPA公司的银杏叶制剂专利网[J].中国中药杂志,2015,40(19):3889.